Trial Information - Phase III
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cance
Disease Specifics: NSCLC
Protocol ID: 61186372NSC3001
Sponsor: JANSSEN
Status: STAR Trial
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
